The Evolving Landscape of Resistance to Osimertinib

J Thorac Oncol. 2020 Jan;15(1):18-21. doi: 10.1016/j.jtho.2019.11.005.

Authors

Adam J Schoenfeld¹, Helena A Yu²

Affiliations

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
² Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. Electronic address: yuh@mskcc.org.

PMID: 31864549
DOI: 10.1016/j.jtho.2019.11.005

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung / genetics*
ErbB Receptors / genetics
Exons
Humans
Lung Neoplasms / genetics*
Mutation
Protein Kinase Inhibitors

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors